3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide | 205187-53-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 英文名称: 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide
• 英文别名: 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin-10,10-dioxide；Tyrima；3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiine 10,10-dioxide
• CAS: 205187-53-7
• 化学式: C₁₄H₈F₄O₄S
• 分子量: 348.275
• InChiKey: PDIMOTRDGUQMNY-UHFFFAOYSA-N

物化性质

• 沸点：
  430.0±45.0 °C(Predicted)
• 密度：
  1.549±0.06 g/cm3(Predicted)
• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  61
• 氢给体数：
  0
• 氢受体数：
  8

制备方法与用途

生物活性

CX-157 是一个可逆的单胺氧化酶-A (MAO-A) 抑制剂，其 EC50 值为 19.3 ng/mL。

靶点

EC50: 19.3 ng/mL (MAO-A)

体内研究

CX-157 是一种可逆的单胺氧化酶-A (MAO-A) 抑制剂，其 EC50 值为 19.3 ng/mL。目前，CX-157 正在研发中，用于治疗重度抑郁症 (MDD)。机制研究表明，在动物模型中，CX-157 可以可逆且竞争性地抑制 MAO-A 活性，从而提高大脑中单胺类神经递质的水平。

反应信息

• 作为产物：
  描述：

  3-Fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 以96的产率得到3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide
  参考文献：
  名称：

  Polymorphic form of fluoro-7-(2,2,2-trifluoroethoxy) phenoxathiin-10,10-dioxide

  摘要：

  本文提供了一种新型的3-氟-7-(2,2,2-三氟乙氧基)苯并噻吩-10,10-二氧化物形式，相对于其他形式的3-氟-7-(2,2,2-三氟乙氧基)苯并噻吩-10,10-二氧化物表现出更高的稳定性。特别是，这种新型形式相对于其他形式可以提供更少的剂量关键的3-氟-7-(2,2,2-三氟乙氧基)苯并噻吩-10,10-二氧化物治疗。本文确定并提供了3-氟-7-(2,2,2-三氟乙氧基)苯并噻吩-10,10-二氧化物的这种新固态形式。这种新型的3-氟-7-(2,2,2-三氟乙氧基)苯并噻吩-10,10-二氧化物固态形式可以通过其任何一种性质进行表征，包括但不限于熔点、差示扫描量热、红外光谱图谱或其部分、溶解度、制备该形式的方法和条件以及从溶液中沉淀的方法，当处于晶体形式时，晶体形式可以根据衍射图案或其部分进行表征。

  公开号：

  US07812050B2

文献信息

• Phenoxathin derivatives as inhibitors of monoamine oxidase
  申请人：Krenitsky Pharmaceuticals, Inc.

  公开号：US06110961A1

  公开（公告）日：2000-08-29

  The present invention provide phenoxathiin compounds useful in the prophylaxis and treatment of mental disorders, such as depression. The present invention also provides a method for treating a mammal having depression, anxiety or other conditions responsive to inhibition of MAO-A. A method of preparing the compounds of the present invention is also provided.

  本发明提供了一种在预防和治疗精神障碍，如抑郁症方面有用的苯氧硫吩化合物。本发明还提供了一种治疗患有抑郁症、焦虑或其他对MAO-A抑制敏感的条件的哺乳动物的方法。同时还提供了一种制备本发明化合物的方法。
• Polymorphic form of fluoro-7-(2,2,2-trifluoroethoxy) phenoxathiin-10,10-dioxide
  申请人：CeNeRx BioPharma, Inc.

  公开号：US07812050B2

  公开（公告）日：2010-10-12

  Provided herein is a new form of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathin 10,10-dioxide, which demonstrates higher stability relative to other forms of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin-10,10-dioxide. In particular, this new form affords less dosage critical administration of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathin 10,10-dioxide relative to other forms. The new solid form of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin-10,10-dioxide has been determined and is provided herein. This new solid form of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin-10,10-dioxide can be characterized by any of a number of its properties, including, but not limited to, melting point, differential scanning calorimetry, infrared spectroscopic spectrum or portions thereof, solubility, methods and conditions under which this form is prepared, and/or precipitated from solution, and, when in crystalline form, the crystalline form can be characterized according to the diffraction pattern or portions thereof.

  本文提供了一种新型的3-氟-7-(2,2,2-三氟乙氧基)苯并噻吩-10,10-二氧化物形式，相对于其他形式的3-氟-7-(2,2,2-三氟乙氧基)苯并噻吩-10,10-二氧化物表现出更高的稳定性。特别是，这种新型形式相对于其他形式可以提供更少的剂量关键的3-氟-7-(2,2,2-三氟乙氧基)苯并噻吩-10,10-二氧化物治疗。本文确定并提供了3-氟-7-(2,2,2-三氟乙氧基)苯并噻吩-10,10-二氧化物的这种新固态形式。这种新型的3-氟-7-(2,2,2-三氟乙氧基)苯并噻吩-10,10-二氧化物固态形式可以通过其任何一种性质进行表征，包括但不限于熔点、差示扫描量热、红外光谱图谱或其部分、溶解度、制备该形式的方法和条件以及从溶液中沉淀的方法，当处于晶体形式时，晶体形式可以根据衍射图案或其部分进行表征。
• PHARMACOLOGICALLY ACTIVE COMPOUNDS AND USE
  申请人：Krenitsky Pharmaceutical Inc

  公开号：EP1021434A2

  公开（公告）日：2000-07-26
• ORAL ANTIDEPRESSANT FORMULATION WITH REDUCED EXCIPIENT LOAD
  申请人：Chen Andrew

  公开号：US20110206769A1

  公开（公告）日：2011-08-25

  Provided are methods for reducing the excipient load of pharmaceutical formulations containing 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide as the active pharmaceutical ingredient, and compositions related thereto. In particular, provided is a pharmaceutical product comprising 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide and a stabilizer admixed throughout a solid-form unilamellar matrix, wherein the ratio of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide to stabilizer ranges from about 2:3 to about 1:10, and related methods of forming the pharmaceutical product.
• ORAL SUSTAINED RELEASE ANTIDEPRESSANT FORMULATION
  申请人：Brand Barry Scott

  公开号：US20120003274A1

  公开（公告）日：2012-01-05

  Pharmaceutical presentations or phenoxathiin-based MAO-A inhibitors are disclosed whereby the MAO receptors are capable of sustained release in the digestive tract. Particular phenoxathiin-based MAO-A inhibitors include those of the following formula: wherein n is 0, 1 or 2; R 1 is a branched or straight chain C1-5 alkyl or C3-6 cycloalkyl optionally substituted with hydroxyl, or one or more halogens; and X 1 , X 2 , X 3 , X 4 , and X 5 are either all hydrogens or one or two of X 1 , X 2 , X 3 , X 4 , and X 5 are halogen and the remainder are hydrogens, with the proviso that when n is 0 or 1 and each X is hydrogen, R 1 is not methyl. A wide variety or sustained release mechanisms can be utilized so as to provide gradual release of the active ingredient after ingestion as a pharmaceutical presentation, such as a tablet or capsule. Presentations include sustained release tablets, sustained release capsules, capsules containing sustained release beads.